Compare QFIN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QFIN | TBPH |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 908.9M |
| IPO Year | 2018 | 2013 |
| Metric | QFIN | TBPH |
|---|---|---|
| Price | $8.49 | $17.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $22.20 | $18.40 |
| AVG Volume (30 Days) | ★ 2.9M | 351.4K |
| Earning Date | 05-18-2026 | 05-04-2026 |
| Dividend Yield | ★ 12.36% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.35 | $13.08 |
| 52 Week High | $32.69 | $21.03 |
| Indicator | QFIN | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 24.46 | 56.07 |
| Support Level | $8.35 | $16.80 |
| Resistance Level | $14.28 | $17.11 |
| Average True Range (ATR) | 0.47 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 3.58 | 25.42 |
Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.